As previously reported, Jefferies upgraded Kodiak Sciences (KOD) to Buy from Hold with a price target of $20, up from $6. With three positive Phase 3 studies with anti-VEGF tarcocimab the firm calls Kodiak “a major turnaround play.” A new near-term catalyst, with VEGF/IL-6 data in MESI inflammation coming soon, brings a “whole new angle of upside indications,” the analyst added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KOD:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue